OBGYN Chemo: Cisplatin

Chemotherapy: Cisplatin.

Cisplatin is a platinum-containing chemotherapeutic agent that exerts its anticancer effects by forming covalent bonds with DNA, particularly with the purine bases of DNA. This covalent binding results in the formation of intra- and inter-strand DNA crosslinks, which interfere with DNA replication and transcription, leading to cell cycle arrest and eventual apoptosis.

Cisplatin has a broad spectrum of antitumor activity and is commonly used in the treatment of solid tumors, such as testicular, ovarian, bladder, lung, and cervical cancers. It is administered intravenously and is rapidly distributed to tissues and fluids throughout the body, including the kidneys. While cisplatin is highly effective in the treatment of cancer, it is also associated with several dose-limiting toxicities, such as nephrotoxicity, ototoxicity, neurotoxicity, and hematological toxicity.

Cisplatin is often used in combination with other chemotherapy drugs to improve treatment outcomes, and there are ongoing efforts to develop new platinum-based drugs that are more effective and have fewer side effects. Despite its limitations, cisplatin remains a cornerstone of chemotherapy and has contributed significantly to the successful treatment of many types of cancer.

Cisplatin Mechanism of Action:
Cisplatin exerts its mechanism of action by forming covalent bonds with DNA, particularly with the purine bases of DNA, which leads to the formation of intra- and inter-strand DNA crosslinks. These crosslinks disrupt the structure of DNA and prevent proper replication and transcription of the DNA molecule.

Intrastrand crosslinks form when cisplatin binds to two adjacent guanine bases on the same DNA strand, causing a kink in the DNA helix. Interstrand crosslinks form when cisplatin binds to guanine bases on opposite strands of DNA, causing a structural distortion in the DNA double helix. Both types of crosslinks lead to the inhibition of DNA replication and transcription, resulting in cell cycle arrest and eventually apoptosis.

Cisplatin also generates reactive oxygen species (ROS) and induces DNA damage response pathways, including the activation of p53, which is a tumor suppressor gene. The activation of p53 leads to the upregulation of genes involved in cell cycle arrest and apoptosis. Additionally, cisplatin can also affect other cellular processes, including the inhibition of RNA and protein synthesis.

While cisplatin is effective in killing cancer cells, it can also damage healthy cells, leading to various side effects, such as nephrotoxicity, ototoxicity, neurotoxicity, and hematological toxicity. As a result, cisplatin is often used in combination with other chemotherapy drugs to improve treatment outcomes and to reduce side effects.

palliative care, cancer care team, cancer treatment guidelines, personalized medicine, nccn